











COVID-19 Vaccines Approved for Use in Canada: mRNA vaccines								
COVID-19 Formulations	Moderna (Spikevax™)	Moderna (Spikevax™)	Moderna (Spikevax™)	Moderna (Spikevax™) Bivalent	Pfizer (Comirnaty™)	Pfizer (Comirnaty™)	Pfizer (Comirnaty™)	Pfizer (Comirnaty™) Bivalent
Vaccine Type	mRNA	mRNA	mRNA	mRNA bivalent	mRNA	mRNA	mRNA	mRNA bivalent
Cap and Label Colour	 Blue cap and label	 Red cap and label	 Red cap and label	 Blue cap and green label	 Maroon cap and label	 Orange cap and label	 Purple cap and label	 Grey cap and label
Authorized Age Group	6 months to 5 years	6 to 11 years	≥12 years	≥18 years	6 months to 4 years	5 to 11 years	≥12 years	≥12 years
Dose and Injection Volume	0.25ml 25 mcg	0.25ml 50 mcg	0.5ml 100 mcg	0.5ml 50 mcg	0.2ml 3 mcg	0.2ml 10 mcg	0.3ml 30 mcg	0.3ml 30 mcg
Dilution	None	None	None	None	2.2ml/vial	1.3ml/vial	1.8ml/vial	None
Routine schedule (primary series)	2 Doses given 8 weeks apart	2 Doses given 8 weeks apart	2 Doses given 8 weeks apart	Not for use in primary series	3 doses, 8 weeks between each dose.	2 Doses given 8 weeks apart	2 Doses given 8 weeks apart	Not for use in primary series.
Booster Dose	N/A	N/A	50 mcg * (6 months after primary series) **	6 months after primary series**	N/A	6 months after primary series	6 months after primary series**	30 mcg (6 months after primary series) **
Date Authorized (primary dose)	July 14/22	Mar 17/22	Aug 27/21	N/A	Sept 9/22	Nov 19/21	Dec 9/20	N/A
Date Authorized (booster dose)	N/A	N/A	N/A	Sept 1/22	N/A	Aug 18/22	Sept 15/21	Oct 7/22
Product Monograph	Moderna PM	Moderna PM	Moderna PM	M/S Bivalent PM	Pfizer PM	Pfizer PM	Pfizer PM	P/C Bivalent PM

*People who are immunocompromised, living in a PCH/EPH, ≥ 70 years or who received 2 non-Health Canada approved vaccines are recommended to have a first booster dose of 100mcg.

**Recommended interval for optimum immune response is 6 months after primary series. The minimum authorized interval is 3 months.

COVID-19 Vaccines Approved for Use in Canada: non-mRNA vaccines		
COVID-19 Formulations	Novavax (Nuvaxovid™)	Janssen (Jcovden™)
Vaccine Type	Protein Subunit	Viral Vector
Cap Colour	 Blue Cap	 Blue Cap
Authorized Age Group	≥18 years	≥18 years
Dose and Injection Volume	0.5ml 5 mcg	0.5ml 5 × 10 ¹⁰ virus particles/0.5 mL
Dilution	None	None
Routine schedule (primary series)	2 Doses given 8 weeks apart	1 dose
Booster Dose	N/A	0.5mL
Date Authorized (primary dose)	Feb 17/22	Mar 5/21
Date Authorized (booster dose)	N/A	May 12/22
Product Monograph	Novavax PM	Janssen PM

Influenza and Pneumococcal Vaccines Approved for Use in Canada: 2022-2023					
Formulations	Fluzone® Quadrivalent	FluLaval® Tetra	Alfurina® Tetra	Fluzone® High Dose	Pneumovax®23 (Pneu-P-23)
Vaccine Type	IIV4-SD	IIV4-SD	IIV4-SD	IIV4-HD	Pneumococcal polysaccharide 23-valent
Supplied	0.5 mL single dose prefilled syringes or 5.0 mL multidose vial.	5.0 mL multidose vial.	0.5 mL single dose prefilled syringes or 5.0 mL multidose vial.	0.7ml Single dose prefilled syringe.	0.5ml
Authorized Age Group	≥ 6 months	≥ 6 months	≥ <u>5 years</u>	≥65 years	≥65 years
Volume	0.5ml	0.5ml	0.5ml	0.7ml	0.5ml
Dose Schedule	*1 or 2 doses: children 6 months to less than 9 years 1 dose: ≥ 9 years	*1 or 2 doses: children 6 months to less than 9 years 1 dose: ≥ 9 years	**1 or 2 doses: children <u>5 years</u> to less than 9 years 1 dose: ≥ 9 years	1 dose	1 dose
Product Monograph	Fluzone PM	FluLaval PM	Afluria PM	High Dose PM	Pneumo PM

* Children 6 months to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.

**Children 5 years to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.